C07D211/88

CRBN LIGANDS AND USES THEREOF
20230234950 · 2023-07-27 ·

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

CRBN LIGANDS AND USES THEREOF
20230234950 · 2023-07-27 ·

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
20220402879 · 2022-12-22 ·

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
20220402879 · 2022-12-22 ·

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

CRBN ligands and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

CRBN ligands and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Hydantoin containing deoxyuridine triphosphatase inhibitors

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Hydantoin containing deoxyuridine triphosphatase inhibitors

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Selective histone deacetylase inhibitors for the treatment of human disease

Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.